Skip to content

13F-HR filed by Sarissa Capital Management LP

Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2023-09-30, filed 2023-11-14, with 11 holding rows worth $742,379,576.

Accession
0000899140-23-001108
Filed
2023-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2023

A holdings report, 11 entries on the cover page, a total value of $742,379,576 stated on the cover page (in dollars after the unit check, H1), rows summing to $742,379,576 with VALUE read as dollars as filed, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ALKERMES PLCG01767105SHS7,042,200$197,252,022dollars as filed
BIOGEN INC COM09062X103Stock643,000$165,257,430dollars as filed
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK16,390,000$157,835,700dollars as filed
INNOVIVA INC45781M101COM7,277,000$94,528,230dollars as filed
Gilead Sciences,Inc.375558103COM920,400$68,974,776dollars as filed
NEUROCRINE BIOSCIENCES INC64125C109COM366,000$41,175,000dollars as filed
AMARIN CORP PLC023111206SPONS ADR NEW10,442,453$9,607,057dollars as filed
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock775,000$5,487,000dollars as filed
VOR BIOPHARMA INC929033108COM618,000$1,310,160dollars as filed
Mersana Therapeutics Inc59045L106Common Stock550,000$698,500dollars as filed
REGULUS THERAPEUTICS INC75915K309COM185,183$253,701dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000899140-23-001108this filing2023-11-14acceptance time not in the bulk data set